<div>Between Visits Adjusted for Multiple Comparisons in a Generalized Linear
Mixed Model. Analysis is based on the 9 subjects completing the trial;
Data is adjusted for baseline severity (using random intercept in the
mixed model linear regression analysis) and the duration of disease for
each subject (<b>Visit 0</b> = baseline; <b>Visit 1</b> =
pre-placebo treatment; <b>Visit 2</b> = post-placebo/pre-benralizumab
visit; <b>Visits 2-4</b> = Benralizumab 30 mg s.c. treatment;<b>Visit 5</b> = 4 week post-Benralizumab visit (determination of
primary efficacy end-point); <b>Visit 6</b> = 8 week post-benralizumab
follow-up visit (determination of long term efficacy and adverse
events); *<i>primary and exploratory outcomes are shaded (Adj p
&lt;.05).</i></div><div><b>Table 2.</b> Differences in Relative Eosinophil Counts
(Eos%) Between Visits in CSU Subjects Before and After Treatment with
Benralizumab</div>